

# UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

19270 U.S.PTO  
10/685199  
  
101403

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application  
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0068US NP1

INVENTORS: Stefan PETRY, et al


TITLE: NOVEL BICYCLIC INHIBITORS OF  
HORMONE SENSITIVE LIPASE

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail in an envelope addressed to Mail Stop  
Patent Application, Commissioner for Patents, P.O.  
Box 1450, Alexandria, VA 22313-1450, on

October 14, 2003

Date of Deposit

Bonnie Stein  
Signature



EL 721892449 US

Express Mail No.

## APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>	Total Pages	<span style="border: 1px solid black; padding: 2px;">68</span>
2. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Sheets	<span style="border: 1px solid black; padding: 2px;">0</span>
3. <input type="checkbox"/> Drawing(s) <i>(35 U.S.C. 113)</i>	Total Pages	<span style="border: 1px solid black; padding: 2px;">2</span>
4. <input type="checkbox"/> Oath or Declaration	Total Sheets	<span style="border: 1px solid black; padding: 2px;">0</span>
a. <input checked="" type="checkbox"/> Newly <u>unexecuted</u> (original or copy)	Total Pages	<span style="border: 1px solid black; padding: 2px;">2</span>
b. <input type="checkbox"/> Copy from a prior application <i>(37 CFR § 1.63(d))</i>		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> <i>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).</i>		
5. <input type="checkbox"/> Power of Attorney	Total Pages	<span style="border: 1px solid black; padding: 2px;">0</span>
a. <input type="checkbox"/> Newly executed (original or copy)		
b. <input type="checkbox"/> Copy from a prior application <i>(37 CFR § 1.63(d))</i>		
6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i>		

## 7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a.  Computer Readable Copy
- b.  Paper Copy (identical to computer copy)
- c.  Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation     Divisional     Continuation-in-part

of prior application no: \_\_\_\_\_, filed \_\_\_\_\_

Examiner \_\_\_\_\_, Group/Art Unit \_\_\_\_\_.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the priority of German Patent Application No. 10247680.2-44, filed 12 October 2002 and claims the benefit of U.S. Provisional Application No. 60/446,913, filed 12 February 2003.  
 The cross reference has been inserted on page one of the specification).

**Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  
 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

**ACCOMPANYING APPLICATION PARTS**

- 7.  Assignment Papers (cover sheet & document(s))
- 8.  37 CFR §3.73(b) Statement  
*(when there is an assignee)*
- 9.  Verified English Translation Document (if applicable)
- 10.  Information Disclosure Statement (IDS)/PTO-1449       Copies of IDS Citations
- 11.  Preliminary Amendment
- 12.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
- 13.  \*Small Entity Statement(s)       Statement filed in prior application,  
*(PTO/SB/09-12)* Status still proper and desired
- 14.  Certified Copy of Priority Document  
*(if foreign priority is claimed)*
- 15.  Other: Application Data Sheet

**CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label

005487
<i>(Insert Customer No. or Attach bar code label here)</i>

*Irving Newman, Reg. No. 22,638  
 Attorney/Agent for Applicant*

Aventis Pharmaceuticals Inc.  
 Patent Department  
 Route #202-206 / P.O. Box 6800  
 Bridgewater, New Jersey 08807-0800  
 Telephone (908) 231-2785  
 Telefax (908) 231-2626  
 Aventis Docket No. DEAV2002/0068US NP1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 770.00)

## Complete if Known

Application Number	To Be Assigned
Filing Date	Concurrently Filed Herewith
First Named Inventor	Stefan Petry, et al
Examiner Name	To Be Assigned
Group / Art Unit	To Be Assigned
Attorney Docket No.	DEAV2002/0068US NP1

## METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  Other  None

 Deposit Account

Deposit Account Number 18-1982

Deposit Account Name Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1001	770	2001	375
1002	340	2002	165
1003	530	2003	260
1004	770	2004	375
1005	160	2005	80
SUBTOTAL (1)		(\$ 770.00)	

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	13	-20** = 0	x 18 = 0
Independent Claims	1	- 3** = 0	x 86 = 0
Multiple Dependent			=

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Code
1202	18	2202 9
1201	86	2201 42
1203	290	2203 140
1204	86	2204 42
1205	18	2205 9
SUBTOTAL (2)		(\$ 0)

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051 65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or cover sheet
1052	50	2052 25	Non-English Specification
1053	130	1053 130	For filing a request for reexamination
1812	2,520	1812 2,520	Requesting publication of SIR prior to Examiner action
1804	920*	1804 920*	Requesting publication of SIR after Examiner action
1805	1,840*	1805 1,840*	Extension for reply within first month
1251	110	2251 55	Extension for reply within second month
1252	420	2252 205	Extension for reply within third month
1253	950	2253 465	Extension for reply within fourth month
1254	1,480	2254 725	Extension for reply within fifth month
1255	2,010	2255 985	Notice of Appeal
1401	330	2401 160	Filing a brief in support of an appeal
1402	330	2402 160	Request for oral hearing
1403	290	2403 140	Petition to institute a public use proceeding
1451	1,510	1451 1,510	Petition to revive - unavoidable
1452	110	2452 55	Petition to revive - unintentional
1453	1,330	2453 650	Utility issue fee (or reissue)
1501	1,330	2501 650	Design issue fee
1502	480	2502 235	Plant issue fee
1503	640	2503 315	Petitions to the Commissioner
1460	130	1460 130	Petitions related to provisional applications
1807	50	1807 50	Submission of Information Disclosure Stmt
1806	180	1806 180	Recording each patent assignment per property (times number of properties)
8021	40	8021 40	Filing a submission after final rejection (37 CFR § 1.129(a))
1809	770	2809 375	For each additional invention to be examined (37 CFR § 1.129(b))
1810	770	2810 375	Request for Continued Examination (RCE)
1801	770	2801 375	Request for expedited examination of a design application
Other fee (specify)			

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

## SUBMITTED BY

Name (Print/Type) Irving Newman, Reg. No. 22,638

Signature

Registration No.  
(Attorney/Agent)

22,638

Telephone (908) 231-2785

Date

October 14 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template